PRASAD RAJU (Chief Financial Officer) sold 81.4% of their position (29.70K shares) of CRISPR THERAPEUTICS AG on the open market
Open‑market sale worth $1.79M — a major position exit. Review remaining holdings and any 10b5‑1 plan disclosures.
Common Shares
Shares
+23.36K
Price / share
$45.15
Trade value
$1.05M
% of position
Common Shares
Shares
+6.34K
Price / share
$44.31
Trade value
$280.88K
% of position
Common Shares
Shares
−18.93K
Price / share
$60.18
Trade value
$1.14M
% of position
Common Shares
Shares
−5K
Price / share
$60.00
Trade value
$300.24K
% of position
Common Shares
Shares
−5.76K
Price / share
$60.21
Trade value
$347.01K
% of position
Net shares
+0.00
Net value
-$451.01K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Shares Direct | 1/6/2026 | M · Option Exercise | +23.36K | $45.15 | $1.05M | 345.2% | 6.77K | 30.13K |
| Common Shares Direct | 1/6/2026 | M · Option Exercise | +6.34K | $44.31 | $280.88K | 21.0% | 30.13K | 36.47K |
| Common Shares Direct | 1/6/2026 | S · Sale | −18.93K | $60.18 | $1.14M | 51.9% | 36.47K | 17.53K |
| Common Shares Direct | 1/6/2026 | S · Sale | −5K | $60.00 | $300.24K | 28.5% | 17.53K | 12.53K |
| Common Shares Direct | 1/6/2026 | S · Sale | −5.76K | $60.21 | $347.01K | 46.0% | 12.53K | 6.77K |
| Total | +0.00 | -$451.01K | ||||||
Stock Option (Right to Buy)
Common Shares
23.36K shares
Shares
−23.36K
Strike price
45.15
Held after
76.64K
Exercisable
—
Stock Option (Right to Buy)
Common Shares
6.34K shares
Shares
−6.34K
Strike price
44.31
Held after
7.49K
Exercisable
—
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Shares23.36K shares | 1/6/2026 | M · Option Exercise | −23.36K | 45.15 | — | 76.64K |
| Stock Option (Right to Buy) Direct | Common Shares6.34K shares | 1/6/2026 | M · Option Exercise | −6.34K | 44.31 | — | 7.49K |